Every 10-Q that Tactile Systems Technology, Inc. (TCMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TCMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCMD filings page.
Tactile Systems Technology (Tactile Medical) reported stronger results for Q2 and the first half of 2026. For the quarter ended June 30, 2026, revenue was $85.7 million, up 9% year over year, with six‑month revenue of $161.0 million, up 15%. Lymphedema products drove growth, contributing 86% of Q2 revenue, while airway clearance products represented 14%.
Gross margin was 76% for both the quarter and year‑to‑date, modestly higher than a year earlier. Q2 net income rose to $7.8 million from $3.2 million, and six‑month net income increased to $6.0 million from $0.2 million, helped by operating leverage and much lower interest expense.
The company closed the LymphaTech acquisition (total consideration $12.1 million, including $8.5 million goodwill) to add 3D measurement technology, and signed a three‑year exclusive distribution deal for the MyoSleeve device with a $3.0 million upfront intangible. AffloVest Gen 6 received FDA 510(k) clearance and launched in June 2026. Tactile ended the quarter with $69.9 million in cash, no borrowings on its $40 million revolver, and recognized about $1.0 million of accrual tied to a government False Claims Act settlement.
Tactile Systems Technology, Inc. reported first‑quarter 2026 revenue of $75.3 million, up 23% from $61.3 million a year earlier, driven by growth in both lymphedema and airway clearance products. Gross margin improved to 77% from 74%, but the company posted a net loss of $1.8 million, narrower than the $3.0 million loss in the prior‑year quarter.
Lymphedema products generated $62.2 million, or 83% of revenue, while airway clearance products contributed $13.0 million, or 17%. Cash was $75.0 million with no borrowings on a $40.0 million revolving credit facility, providing liquidity alongside ongoing share repurchases of $1.1 million in the quarter.
During the quarter, Tactile Systems closed the LymphaTech acquisition for $7.2 million in cash plus contingent consideration initially valued at $4.9 million, adding 3D measurement technology and $8.5 million of goodwill. The company also recorded a $1.0 million accrual tied to an agreement in principle to settle previously disclosed False Claims Act lawsuits.
Tactile Systems Technology, Inc. reported higher revenue and profits in its quarterly report for the period ended September 30, 2025. Revenue rose to $85.8 million, up from $73.1 million a year earlier, driven by both lymphedema and airway clearance products. Airway clearance revenue grew strongly to $13.4 million, while lymphedema products contributed $72.4 million. Gross margin improved to 76% as revenue outpaced cost growth.
Net income increased to $8.2 million versus $5.2 million a year ago, with diluted earnings per share of $0.36. For the first nine months of 2025, revenue reached $225.9 million and net income was $8.5 million. Operating cash flow was strong at $25.5 million, supporting capital spending and shareholder returns.
The company ended the quarter with $66.0 million in cash and no outstanding borrowings under its revised credit facility, after paying off a term loan earlier in the year. It completed a $30.0 million share repurchase program, retiring about 2.34 million shares, and later authorized a new $25.0 million repurchase program extending to November 3, 2027. Shares outstanding were 22.3 million as of September 30, 2025.